16 stories mentioning EYPTUpdated just now
Every FINWIRES story that references EYPT, newest first.
EyePoint Pharmaceuticals (EYPT) has an average rating of overweight and mean price target of $34.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
EyePoint's (EYPT) phase 3 Lugano trial's failure to meet its primary endpoint raises concerns about Duravyu's potential risks in certain patients and whether data from the second pivotal trial Lucia alone could support regulatory approval, RBC Capital Markets said in a note emailed Tuesday.The Lucia trial is slightly bigger than the Lugano trial, with topline results expected in Q4. If Lucia meets its primary endpoint, EyePoint said it plans to file for US Food and Drug Administration approval in H1 2027.A single-trial filing could be challenging, as the FDA may require a stricter non-inferiority standard or longer safety follow-up, analysts said.Overall, Lucia data could provide a path forward, but uncertainty around the clinical and regulatory outlook is likely to remain until the results are available and EyePoint gets clearer guidance from regulators, analysts said.RBC Capital Markets downgraded EyePoint to sector perform speculative risk from outperform, and cut its price target to $5 from $37.Price: $5.29, Change: $+0.42, Percent Change: +8.62%
EyePoint Pharmaceuticals (EYPT) has an average rating of overweight and mean price target of $34.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
EyePoint (EYPT) has an average rating of buy and mean price target of $34.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
EyePoint Pharmaceuticals (EYPT) has an average rating of buy and mean price target of $34.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.2%.The iShares Biotechnology ETF (IBB) added 1.8%.In corporate news, OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery program, while raising its fiscal 2026 cash and cash equivalents guidance. OmniAb shares jumped nearly 13%, and Lilly was up 0.4%.Freenome (FRNM) shares surged past 12% after Jefferies initiated coverage of the stock with a buy rating and a price target of $17.Argenx (ARGX) shares climbed 16% after the company said a phase 3 study evaluating its experimental drug Vyvgart Hytrulo in adults with autoimmune myositis met its main goal.EyePoint (EYPT) shares tumbled 67% after it said its phase 3 Lugano trial testing Duravyu in people with wet age-related macular degeneration failed to achieve its primary endpoint.
EyePoint (EYPT) said its phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint. JPMorgan downgraded EyePoint to neutral from overweight.Shares slumped 69% as intraday trading volume catapulted to almost 40.4 million from a daily average of about 1.48 million.Enovix (ENVX) Chief Executive Officer and director Raj Talluri resigned on Aug. 13 to pursue another opportunity, the company said Monday. The company named Chief Financial Officer Ryan Benton interim CEO while conducting an internal and external search for a permanent CEO.Shares plunged 18% as intraday trading volume catapulted to over 24.4 million from a daily average of more than 6.45 million.Corvex (MOVE) reported a wider Q2 loss amid a surge in year-over-year sales late Friday.Shares declined 10%, with intraday trading volume at over 66,000, versus a daily average of about 183,000.Price: $4.53, Change: $-10.23, Percent Change: -69.32%
Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate news, UroGen Pharma (URGN) shares rose 2.1% after the firm said it has submitted a new drug application to the US Food and Drug Administration for UGN-103 to treat adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.Argenx (ARGX) shares surged past 16% after the company said a phase 3 study evaluating its experimental drug Vyvgart Hytrulo in adults with autoimmune myositis met its main goal.Mesoblast (MESO) shares jumped nearly 10% after the company said it has completed patient treatment in a phase 3 trial of its experimental rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.EyePoint (EYPT) shares tumbled 68% after it said its phase 3 Lugano trial testing Duravyu in people with wet age-related macular degeneration failed to achieve its primary endpoint.
EyePoint Pharmaceuticals (EYPT) has an average rating of buy and mean price target of $38.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $4.57, Change: $-10.18, Percent Change: -69.02%
The Nasdaq Composite was up, while the Dow Jones Industrial Average and S&P 500 Index were down in late-morning trading Monday, as oil prices rose amid ongoing tensions in the Middle East.In company news, Nvidia (NVDA) said Monday it is investing $1.5 billion in SB Energy to support its growth as an artificial intelligence infrastructure developer. The chipmaker has entered into a partnership with SB Energy to become the exclusive AI compute infrastructure provider at the PORTS-Pike Technology Campus in Pike County, Ohio. SB Energy will build, own and operate the data center under a 20-year lease to Microsoft-backed (MSFT) OpenAI, which will use the capacity, according to a statement. Nvidia shares were up 1.1%, while Microsoft shares were down 2.2%.L3Harris Technologies (LHX) said Monday it has appointed Sam Mehta as president and chief executive, replacing Christopher Kubasik, who stepped down as chairman and CEO following an investigation into conduct the company said was inconsistent with its code of conduct. Mehta, who joined L3Harris in 2023, most recently led the Space & Mission Systems and Communications & Spectrum Dominance segments. L3Harris shares were down 4.1%.Amazon-backed (AMZN) Anthropic told potential investors that its Q2 revenue jumped at least 14-fold from the year prior to over $11.5 billion, Bloomberg reported, citing internal documents it viewed. Amazon shares were down 0.4%.EyePoint (EYPT) said Monday its Phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint. The drug missed the main visual acuity goal in the complete dataset because of a patient subgroup with vision loss unrelated to the condition, the company said. EyePoint shares were down 69.3%.Palantir Technologies (PLTR) Co-Founder Peter Thiel has acquired over 1.1 million American depositary shares in Vista Energy (VIST) worth about $75.9 million, according to a filing with the US Securities and Exchange Commission. Palantir shares were up 0.5%.Madison Air Solutions (MAIR) signed a definitive deal to acquire ebm-papst, which specializes in airflow technology, for $5.40 billion, or $5 billion net of future tax savings, the company said Monday. The deal is expected to close around the end of the year, Madison said. Madison Air shares were down 4.4%.Price: $227.00, Change: $+1.84, Percent Change: +0.82%
Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.2%.Argenx (ARGX) shares were up more than 11% after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.EyePoint (EYPT) stock was down past 69% after the company said its phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint.Mesoblast (MESO) shares were up nearly 10% after the company said it has completed patient treatment in a phase 3 trial of its experimental rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.
EyePoint (EYPT) said Monday its Phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint.The drug missed the main visual acuity goal in the complete dataset because of a patient subgroup with vision loss unrelated to the condition, the company said.However, Duravyu demonstrated non-inferiority to control treatment aflibercept in an ad hoc analysis that excluded those patients, EyePoint said.The company said it expects topline data from a second Phase 3 trial in Q4 and foresees a potential regulatory submission in H1 2027.Shares of the company fell more than 65% in recent premarket activity Monday.Price: $5.14, Change: $-9.62, Percent Change: -65.19%
Ocular Therapeutix's (OCUL) regulatory plans for Axpaxli in wet age-related macular degeneration remain on track, with a pre-new drug application scheduled for Q3, an NDA filing planned for Q4, and a potential commercial launch in 2027, RBC Capital Markets said in a note Monday.RBC noted that EyePoint's (EYPT) first wet AMD readout is due soon and expects Ocular's data to receive a positive reaction if the competitor's data meets expectations or is mixed.However, the brokerage is more cautious about the initial share reaction if EyePoint misses on efficacy or significantly exceeds expectations, according to the note.RBC sees 20% weighted-average upside potential into the EyePoint data, and continues to see room for both tyrosine kinase inhibitors, if approved. It currently expects Axpaxli to generate peak US revenue of $1.2 billion, and assumes competition from EyePoint.Ocular already has in-house manufacturing in place for Axpaxli, with sufficient doses to satisfy the initial launch, and plans to expand manufacturing sites further to support a future launch expansion into diabetic retinopathy, the note said.RBC kept an outperform speculative risk rating at Ocular Therapeutix with a price target of $30.Price: $8.57, Change: $+0.16, Percent Change: +1.96%
EyePoint (EYPT) said Thursday it has completed patient enrollment in two of its phase 3 clinical trials evaluating Duravyu for the treatment of diabetic macular edema.The company said it has enrolled over 480 patients across both trials, ahead of schedule.EyePoint said it expects to report topline data for both trials in Q4 2027.Shares of the company were up 2.3% in Thursday trading.Price: $12.17, Change: $+0.25, Percent Change: +2.10%
EyePoint Pharmaceuticals (EYPT) has agreed to pay about $4.66 million to settle allegations that it violated the False Claims Act by providing kickbacks to encourage ambulatory service centers to buy and dispense the Dexycu injectable drug from January 2019 to March 1, 2023, the US Department of Justice said Friday.As part of the settlement, EyePoint entered into a five-year corporate integrity agreement, agreed to pay an additional $21,518.68 to certain participating states, and resolved whistleblower claims, with the relator set to receive about $792,000, according to a statement.EyePoint Pharmaceuticals shares were up 4.2% in Friday trading.Price: $13.59, Change: $+0.55, Percent Change: +4.22%
EyePoint Pharmaceuticals (EYPT) has an average rating of buy and mean price target of $40.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
